**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 22-year-old woman developed coronavirus disease-2019 (COVID-19) following chemotherapy with doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide, cyclophosphamide, vincristine, procarbazine, prednisolone, ifosfamide, carboplatin, brentuximab-vedotin and pembrolizumab for Hodgkin lymphoma \[HL; *routes not stated; not all dosages stated*\].

The woman presented on 14 March 2020 with pyrexia, chills, rigors, sore throat and cough for 3 days. She was diagnosed with HL in May 2017 following which she received various chemotherapeutic drugs. She started receiving two cycles of ABVD regimen, comprising doxorubicin \[adriamycin\], bleomycin, vinblastine and dacarbazine with escalation to escBEACOPP regimen, comprising bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone for four cycles because of suboptimal response. In February 2018, positron emission tomography (PET) showed progressive disease, and hence, she started receiving salvage therapy with three cycles of ICE regimen, comprising of ifosfamide, carboplatin and etoposide. A repeat PET scan showed chemo-refractory disease, and subsequently, she received three cycles of brentuximab-vedotin with a suboptimal response. In January 2019, she underwent radiotherapy. However, in June 2019, she developed recurrence of HL. In July 2019, she started receiving six-weekly pembrolizumab 400mg. She was due for seventh cycle of pembrolizumab 11 days into inpatient stay on 23 March 2020. At presentation, her vitals revealed low-grade pyrexia. Laboratory findings were as follows: temperature 37.9°C, respiratory rate 18, heart rate 65, BP 120/84 and oxygen saturation 96% on room air \[*not all units stated*\]. She was lymphopenic and exhibited raised levels of CRP as well as lactate dehydrogenase. Her platelets dropped transiently while an inpatient.

The woman started receiving antibiotic therapy with piperacillin/tazobactam and doxycycline on day 1 of hospitalisation with suspicion of community-acquired pneumonia (differential diagnosis), while her swab results were pending for severe acute respiratory syndrome coronavirus-2. Subsequently, she was diagnosed with COVID-19, which was attributed to her malignancy and chemotherapy. She then started receiving lopinavir/ritonavir on day 2. Her antibiotic therapy was continued. Pembrolizumab dose was held. Within the initial 6 days of her hospital stay, she was pyrexic and required oxygen. Chest X-ray demonstrated bi-basal crackles on auscultation of lung fields and evolving infiltrates in the lower zones bilaterally. In addition, she exhibited shortness of breath. Her supplementary oxygen requirements increased from 0% (on day 1) to a fraction of inspired oxygen of 40% (on day 6). Until day 7 (i.e. day 6 of lopinavir/ritonavir), her therapy was not altered throughout that period with the development of new diarrhoea. Lopinavir/ritonavir and antibiotics were stopped. At that time, her therapy was replaced by hydroxychloroquine and azithromycin. All the drugs (piperacillin/tazobactam, doxycycline, lopinavir/ritonavir, hydroxychloroquine and azithromycin) that she received as treatment for COVID-19 were off-label. She remained febrile until day 13 of symptoms (i.e. day 10 of hospitalisation and day 2 of hydroxychloroquine as well as azithromycin). Thereafter, CRP levels decreased, and improvement in oxygenation as well as resolution of symptoms were observed. At the time of discharge (i.e. on day 16 of symptoms and day 13 of hospitalisation), she was apyrexic, well and had no supplemental oxygen requirements.
